Seminars in Nephrology
Volume 25, Issue 4 , Pages 246-251 , July 2005

Pathologic Basis and Treatment Considerations in Chronic Kidney Disease-Related Hypertension

  • Domenic Sica

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Domenic A. Sica, MD, Professor of Medicine and Pharmacology, Chairperson, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Box 980160, MCV Station, Virginia Commonwealth University Health System, Richmond, VA 23298-0160
    • ,
  • Dan Carl

References 

  1. US Renal Data System . USRDS 2000 Annual Report . Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2000;
  2. Centers for Disease Control and Prevention . State-specific trends in chronic kidney failure-United States, 1990–2001 . MMWR Morb Mortal Wkly Rep . 2001;53:918–920
  3. National Kidney Foundation . K/DOQI clinical practice guidelines for chronic kidney disease (Evaluation, classification and stratification) . Am J Kidney Dis . 2002;39(suppl 1):S1–S266
  4. Mailloux LU . Hypertension in patients with chronic renal disease . Am J Kidney Dis . 1998;32(suppl 3):S120–S141
  5. National Kidney Foundation . K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease . Am J Kidney Dis . 2004;43(suppl 1):S1–S290
  6. De Nicola L , Minutolo R , Bellizzi V , et al.   Achievement of target blood pressure levels in chronic kidney disease (A salty question?) . Am J Kidney Dis . 2004;43:782–795
  7. Vasavada N , Agarwal R . Role of excess volume in the pathophysiology of hypertension in chronic kidney disease . Kidney Int . 2003;64:1772–1779
  8. Neff MS , Kim KE , Persoff M , et al.   Hemodynamics of uremic anemia . Circulation . 1971;43:876–883
  9. Safar ME , London GM , Weiss YA , et al.   Overhydration and renin in hypertensive patients with terminal renal failure; a hemodynamic study . Clin Nephrol . 1975;5:183–188
  10. Kooman JP , Van Der Sande FM , Leunissen KM . Role of sodium and volume in the pathogenesis of hypertension in dialysis patients. Reflections on pathophysiological mechanisms . Blood Purif . 2004;22:55–59
  11. Mailloux LU . Hypertension in chronic renal failure and ESRD (Prevalence, pathophysiology, and outcomes) . Semin Nephrol . 2001;21:146–156
  12. Agarwal R . Proinflammatory effects of oxidative stress in chronic kidney disease (Role of additional angiotensin II blockade) . Am J Physiol . 2003;284:F863–F869
  13. Lariviere R , Lebel M . Endothelin-1 in chronic renal failure and hypertension . Can J Physiol Pharmacol . 2003;81:607–621
  14. Freel EM , Connell JM . Mechanisms of hypertension (the expanding role of aldosterone) . J Am Soc Nephrol . 2004;15:1993–2001
  15. McLaughlin N , Gehr TWB , Sica DA . Aldosterone receptor antagonism and end-stage renal disease . Curr Hypertens Rep . 2004;6:327–330
  16. Sato A , Hayashi K , Saruta T . Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease . Am J Hypertens . 2005;18:44–49
  17. Epstein M , Buckalew V , Martinez F , et al.   Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination in diabetic hypertensives with microalbuminuria . Am J Hypertens . 2002;15(suppl 1):A24
  18. Campese VM , Romoff MS , Levitan D , et al.   Mechanisms of autonomic nervous system dysfunction in uremia . Kidney Int . 1981;20:246–253
  19. Neumann J , Ligtenberg G , Klein II , et al.   Sympathetic hyperactivity in chronic kidney disease (Pathogenesis, clinical relevance, and treatment) . Kidney Int . 2004;65:1568–1576
  20. Laederach K , Weidmann P . Plasma and urinary catecholamines in relation to renal function in man . Kidney Int . 1987;31:107–111
  21. Converse RL , Jacobsen TN , Toto RD , et al.   Sympathetic overactivity in patients with chronic renal failure . N Engl J Med . 1992;327:1912–1918
  22. Odar-Cederlof I , Ericcson F , Theodorsson E , et al.   Is neuropeptide Y a contributor to volume-induced hypertension . Am J Kidney Dis . 1998;31:803–808
  23. Zoccali C , Mallamaci F , Tripepi G , et al.   Neuropeptide Y, left ventricular mass and function in patients with end stage renal disease . J Hypertens . 2003;21:1355–1362
  24. Modlinger PS , Wilcox CS , Aslam S . Nitric oxide, oxidative stress, and progression of chronic renal failure . Semin Nephrol . 2004;24:354–365
  25. Zoccali C , Mallamaci F , Tripepi G . Novel cardiovascular risk factors in end-stage renal disease . J Am Soc Nephrol . 2004;15:S77–S80
  26. Kielstein JT , Boger RH , Bode-Boger SM , et al.   Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease (Relationship to treatment method and atherosclerotic disease) . J Am Soc Nephrol . 1999;10:594–600
  27. Scroider M , Riedel E , Beck W , et al.   Increased reduction of dimethylarginines and lowered interdialytic blood pressure by the use of biocompatible membranes . Kidney Int . 2001;78(suppl 1):S19–S24
  28. Nishimura M , Takahashi H , Maruyama K , et al.   Enhanced production of nitric oxide may be involved in acute hypotension during maintenance hemodialysis . Am J Kidney Dis . 1998;31:809–817
  29. Khosla UM , Johnson RJ . Hypertension in hemodialysis patients and the “lag phenomenon” (insights into pathophysiology and clinical management) . Am J Kidney Dis . 2004;43:739–751
  30. Avendano C , Alvarez JS , Sacristan JA , et al.   Interference of digoxin-like immunoreactive substances with TDx digoxin II assay in different patients . Ther Drug Monit . 1991;13:523–527
  31. Bisordi JE , Holt S . Digitalis-like immunoreactive substances and extracellular fluid volume status in chronic hemodialysis patients . Am J Kidney Dis . 1989;13:396–403
  32. Rostand SG , Drueke TB . Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure . Kidney Int . 1999;56:383–392
  33. Ogata H , Ritz E , Odoni G , et al.   Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors . J Am Soc Nephrol . 2003;14:959–967
  34. Johnson RJ , Feig DI , Herrera-Acosta J , et al.   Resurrection of uric acid as a causal risk factor in essential hypertension . Hypertension . 2005;45:18–20
  35. Kang DH , Nakagawa T . Uric acid and chronic renal disease (Possible implication of hyperuricemia on progression of renal disease) . Semin Nephrol . 2005;25:43–49
  36. Mazzali M , Hughes J , Kim YG , et al.   Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism . Hypertension . 2001;38:1101–1106
  37. Sánchez-Lozada LG , Tapia E , Santamaria J , et al.   Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats . Kidney Int . 2005;67:237–247
  38. Watanabe S , Kang DH , Feng L , et al.   Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity . Hypertension . 2002;40:355–360
  39. Sica DA , Schoolwerth A . Uric acid and losartan . Curr Opin Nephrol Hypertens . 2002;11:475–482
  40. Parker KP . Sleep disturbances in dialysis patients . Sleep Med Rev . 2003;7:131–143
  41. Zoccali C , Mallamaci F , Tripepi G . Sleep apnea in renal patients . J Am Soc Nephrol . 2001;12:2854–2859
  42. Crabtree D , Morgan B , Skatrud J . Chemoreflex sensitization augments sympathetic vasomotor outflow in awake humans . Am Rev Respir Dis . 1993;147:A1015; (abstr)
  43. Textor SC . Ischemic nephropathy (Where are we now?) . J Am Soc Nephrol . 2004;15:1974–1982
  44. Textor SC , Novick AC , Steinmuller DR , et al.   Renal failure limiting antihypertensive therapy as an indication for renal revascularization . Arch Intern Med . 1983;143:2208–2211
  45. Lam YW , Banerji S , Hatfield C , et al.   Principles of drug administration in renal insufficiency . Clin Pharmacokinet . 1997;32:30–57
  46. Olyaei AJ , De Mattos AM , Bennett WM . Prescribing drugs in renal disease . In:  Brenner B ,  Rector F editor. The Kidney . (6th ed). Philadelphia: WB Saunders; 2000;p. 2606–2653
  47. Sica DA . Kinetics of angiotensin converting enzyme inhibitors in renal failure . J Cardiovasc Pharmacol . 1992;20(suppl 10):S13–S20
  48. Frishman WH , Alwarshetty M . β-adrenergic blockers in systemic hypertension . Clin Pharmacokinet . 2002;41:505–516
  49. Bakris GL , Williams M , Dworkin L , et al.  National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group   Preserving renal function in adults with hypertension and diabetes (A consensus approach) . Am J Kidney Dis . 2000;36:646–661
  50. Yu HT . Progression of chronic renal failure . Arch Intern Med . 2003;163:1417–1429
  51. de Zeeuw D , Remuzzi G , Parving HH , et al.   Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy (Lessons from RENAAL) . Kidney Int . 2004;65:2309–2320
  52. Aros C , Remuzzi G . The renin-angiotensin system in progression, remission and regression of chronic nephropathies . J Hypertens . 2002;20(suppl 3):S45–S53
  53. Coresh J , Astor B , Sarnak MJ . Evidence for increased cardiovascular disease risk in patients with chronic kidney disease . Curr Opin Nephrol Hypertens . 2004;13:73–81
  54. Locatelli F , Del Vecchio L , Pozzoni P , et al.   Is it the agent or the blood pressure level that matters for renal and vascular protection in chronic nephropathies? . Kidney Int . 2005;93(suppl 1):S15–S19
  55. Sarnak MJ , Greene T , Wang X , et al.   The effect of a lower target blood pressure on the progression of kidney disease (Long-term follow-up of the modification of diet in renal disease study) . Ann Intern Med . 2005;142:342–351
  56. Bidani AK , Griffin KA . Pathophysiology of hypertensive renal damage (Implications for therapy) . Hypertension . 2004;44:595–601
  57. Mentari E , Rahman M . Blood pressure and progression of chronic kidney disease (Importance of systolic, diastolic, or diurnal variation) . Curr Hypertens Rep . 2004;6:400–404
  58. Buter H , Hemmelder MH , Navis G , et al.   The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide . Nephrol Dial Transplant . 1998;13:1682–1685
  59. Sica DA , Gehr TW . Diuretic use in stage 5 chronic kidney disease and end-stage renal disease . Curr Opin Nephrol Hypertens . 2003;12:483–490
  60. Sica DA . Metolazone and its role in edema management . Congest Heart Fail . 2003;9:100–105
  61. Epstein M . Role of aldosterone blockade in the management of hypertension and cardiovascular disease . Contrib Nephrol . 2004;143:90–104
  62. Sica DA . Eplerenone: A new aldosterone receptor antagonist: Are the FDA’s restrictions appropriate . J Clin Hypertens . 2002;4:441–445

PII: S0270-9295(05)00044-6

doi: 10.1016/j.semnephrol.2005.03.001

Seminars in Nephrology
Volume 25, Issue 4 , Pages 246-251 , July 2005

Article Tools

* Image Usage & Resolution